These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 22564831)
1. Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. Choi GE; Min KN; Won CJ; Jeon K; Shin SJ; Koh WJ Antimicrob Agents Chemother; 2012 Jul; 56(7):3549-55. PubMed ID: 22564831 [TBL] [Abstract][Full Text] [Related]
2. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Choi GE; Shin SJ; Won CJ; Min KN; Oh T; Hahn MY; Lee K; Lee SH; Daley CL; Kim S; Jeong BH; Jeon K; Koh WJ Am J Respir Crit Care Med; 2012 Nov; 186(9):917-25. PubMed ID: 22878281 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. Zhang Z; Lu J; Liu M; Wang Y; Zhao Y; Pang Y Int J Antimicrob Agents; 2017 Mar; 49(3):383-386. PubMed ID: 28188830 [TBL] [Abstract][Full Text] [Related]
5. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense. Chu HS; Chang SC; Shen EP; Hu FR PLoS One; 2015; 10(1):e0116236. PubMed ID: 25581038 [TBL] [Abstract][Full Text] [Related]
7. [In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates]. Sürücüoğlu S; Özkütük N; Gazi H; Çavuşoğlu C Mikrobiyol Bul; 2023 Oct; 57(4):639-649. PubMed ID: 37885391 [TBL] [Abstract][Full Text] [Related]
8. The drug susceptibility profile and inducible resistance to macrolides of Mycobacterium abscessus and Mycobacterium massiliense in Korea. Kim SY; Kim CK; Bae IK; Jeong SH; Yim JJ; Jung JY; Park MS; Kim YS; Kim SK; Chang J; Kang YA Diagn Microbiol Infect Dis; 2015 Feb; 81(2):107-11. PubMed ID: 25467784 [TBL] [Abstract][Full Text] [Related]
9. Comparison of drug-susceptibility patterns and gene sequences associated with clarithromycin and azithromycin resistance in Yoshida S; Tsuyuguchi K; Kobayashi T; Inoue Y; Suzuki K J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33570485 [No Abstract] [Full Text] [Related]
10. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. Jeong SH; Kim SY; Huh HJ; Ki CS; Lee NY; Kang CI; Chung DR; Peck KR; Shin SJ; Koh WJ Int J Infect Dis; 2017 Jul; 60():49-56. PubMed ID: 28522316 [TBL] [Abstract][Full Text] [Related]
11. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. Maurer FP; Castelberg C; Quiblier C; Böttger EC; Somoskövi A J Antimicrob Chemother; 2014 Jun; 69(6):1559-63. PubMed ID: 24500188 [TBL] [Abstract][Full Text] [Related]
12. Impact on Macrolide Resistance of Genetic Diversity of Mycobacterium abscessus Species. Jong BE; Wu TS; Chen NY; Yang CH; Shu CC; Wang LS; Wu TL; Lu JJ; Chiu CH; Lai HC; Chung WH Microbiol Spectr; 2022 Dec; 10(6):e0274922. PubMed ID: 36416559 [TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease. Choi H; Kim SY; Lee H; Jhun BW; Park HY; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin SJ; Daley CL; Koh WJ Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872066 [TBL] [Abstract][Full Text] [Related]
14. Preliminary Study on Drug Susceptibility Profile and Resistance Mechanisms to Macrolides of Clinical Isolates of Non-tuberculous Mycobacteria from China. Li F; Li GL; Pang H; Liu HC; Xiao TY; Li SJ; Luo Q; Jiang Y; Wang RB; Wan KL Biomed Environ Sci; 2018 Apr; 31(4):290-299. PubMed ID: 29773092 [TBL] [Abstract][Full Text] [Related]
16. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. Bermudez LE; Kolonoski P; Petrofsky M; Wu M; Inderlied CB; Young LS J Infect Dis; 2003 Jun; 187(12):1977-80. PubMed ID: 12792877 [TBL] [Abstract][Full Text] [Related]
17. Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. Chew KL; Cheng JWS; Hudaa Osman N; Lin RTP; Teo JWP J Med Microbiol; 2017 Oct; 66(10):1443-1447. PubMed ID: 28874233 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility profiles of Mycobacterium abscessus complex isolates from respiratory specimens in Shanghai, China. Guo Q; Wei J; Zou W; Li Q; Qian X; Zhu Z J Glob Antimicrob Resist; 2021 Jun; 25():72-76. PubMed ID: 33689828 [TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546 [TBL] [Abstract][Full Text] [Related]
20. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Bastian S; Veziris N; Roux AL; Brossier F; Gaillard JL; Jarlier V; Cambau E Antimicrob Agents Chemother; 2011 Feb; 55(2):775-81. PubMed ID: 21135185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]